Mild heart failure is a mortality marker after a non-ST-segment acute myocardial infarction

Iván J Núñez-Gil1, Juan C García-Rubira, María Luaces

  • 1Cardiovascular Institute, Hospital Clínico San Carlos, Plaza Cristo Rey, Madrid, Spain. ibnsky@yahoo.es

Insights

Mild heart failure (HF) in non-ST-elevation myocardial infarction (NSTEMI) indicates a poor prognosis and increased mortality. Early cardiac catheterization and revascularization are recommended for these patients.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • The Killip classification is used to assess heart failure (HF) severity in acute myocardial infarction (MI).
  • Non-ST-elevation myocardial infarction (NSTEMI) is a growing concern, yet the prognostic value of mild HF (low Killip class) in NSTEMI requires further investigation.

Purpose of the Study:

  • To evaluate the prognostic significance of mild heart failure in patients presenting with NSTEMI.
  • To determine if low Killip class scores in NSTEMI correlate with adverse cardiovascular outcomes.

Main Methods:

  • A prospective study of 835 NSTEMI patients (2005-2007) was conducted.
  • Patients were categorized into Killip class 1 (K1, n=684) or Killip class 2 (K2, n=113); those with K>2 were excluded.
  • Data collected included clinical characteristics, angiographic findings, treatment strategies, and 30-day mortality and major adverse cardiovascular events (MACE).

Main Results:

  • Killip-2 patients were older, more frequently female, and had higher rates of diabetes and hypertension compared to Killip-1 patients.
  • Infarction size and history of previous MI/revascularization were similar between groups.
  • Killip-2 patients experienced worse outcomes, including higher mortality and MACE (p<0.001). Mild HF (K2) was an independent predictor of mortality (OR=6.50; 95% CI: 2.48-16.95; p<0.001).

Conclusions:

  • Mild heart failure at presentation in NSTEMI patients is associated with a poor prognosis and elevated short-term mortality.
  • An aggressive management strategy, including early cardiac catheterization and revascularization, should be considered for NSTEMI patients with mild HF.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...